{
    "organizations": [],
    "uuid": "0c8fe2bc52863ab85509780866fc6d2d4fac9794",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/04/26/globe-newswire-akcea-therapeutics-to-hold-first-quarter-2018-financial-results-webcast.html",
    "ord_in_thread": 0,
    "title": "Akcea Therapeutics to Hold Financial Results Webcast",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "CAMBRIDGE, Mass., April 26, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (Nasdaq:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Thursday, May 3 rd at 4:30 p.m. Eastern Time to discuss its first quarter 2018 financial results and report on pipeline and business progress.\nInterested parties may listen to the call by dialing (855) 237-2439, passcode 1497015, or access the webcast at www.akceatx.com . A webcast replay will be available for a limited time at the same address.\nABOUT AKCEA THERAPEUTICS\nAkcea Therapeutics, an affiliate of Ionis Pharmaceuticals, Inc. (Nasdaq:IONS), is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. Akcea is advancing a mature pipeline of six novel drugs, including inotersen, volanesorsen, AKCEA-APO(a)-L Rx , AKCEA-ANGPTL3-L Rx , AKCEA-APOCIII-L Rx , and AKCEA-TTR-L Rx , all with the potential to treat multiple diseases. All six drugs were discovered by and are being co-developed with Ionis, a leader in antisense therapeutics, and are based on Ionis’ proprietary antisense technology. Inotersen is under regulatory review in the U.S. and EU for the treatment of hereditary amyloid transthyretin amyloidosis (hATTR) amyloidosis. Volanesorsen is under regulatory review in the U.S., EU and Canada for the treatment of familial chylomicronemia syndrome, or FCS, and is currently in Phase 3 clinical development for the treatment of familial partial lipodystrophy, or FPL. Akcea is building the infrastructure to commercialize its drugs globally. Akcea is a global company headquartered in Cambridge, Massachusetts. Additional information about Akcea is available at www.akceatx.com .\nFORWARD-LOOKING STATEMENT\nThis press release includes forward-looking statements regarding the business of Akcea Therapeutics, Inc. and the therapeutic and commercial potential of inotersen, volanesorsen and other products in development. Any statement describing Akcea’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Akcea’s forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Akcea’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Akcea. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Akcea’s programs are described in additional detail in its annual report on Form 10-K for the year ended December 31, 2017, which is on file with the SEC.\nIn this press release, unless the context requires otherwise, “Ionis”, “Akcea,” “Company,” “Companies” “we,” “our,” and “us” refers to Ionis Pharmaceuticals and/or Akcea Therapeutics.\nIonis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of Akcea Therapeutics, Inc.\nMedia and Investor Contacts:\nKathleen Gallagher\nHead of Communications and Investor Relations\n617-207-8509\nkgallagher@akceatx.com\nSource:Akcea Therapeutics, Inc.",
    "published": "2018-04-26T15:00:00.000+03:00",
    "crawled": "2018-04-26T18:17:51.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "cambridge",
        "april",
        "globe",
        "newswire",
        "akcea",
        "therapeutic",
        "nasdaq",
        "akca",
        "affiliate",
        "ionis",
        "pharmaceutical",
        "announced",
        "today",
        "host",
        "live",
        "webcast",
        "thursday",
        "may",
        "rd",
        "eastern",
        "time",
        "discus",
        "first",
        "quarter",
        "financial",
        "result",
        "report",
        "pipeline",
        "business",
        "progress",
        "interested",
        "party",
        "may",
        "listen",
        "call",
        "dialing",
        "passcode",
        "access",
        "webcast",
        "webcast",
        "replay",
        "available",
        "limited",
        "time",
        "address",
        "akcea",
        "therapeutic",
        "akcea",
        "therapeutic",
        "affiliate",
        "ionis",
        "pharmaceutical",
        "nasdaq",
        "ion",
        "biopharmaceutical",
        "company",
        "focused",
        "developing",
        "commercializing",
        "drug",
        "treat",
        "patient",
        "serious",
        "rare",
        "disease",
        "akcea",
        "advancing",
        "mature",
        "pipeline",
        "six",
        "novel",
        "drug",
        "including",
        "inotersen",
        "volanesorsen",
        "rx",
        "rx",
        "rx",
        "rx",
        "potential",
        "treat",
        "multiple",
        "disease",
        "six",
        "drug",
        "discovered",
        "ionis",
        "leader",
        "antisense",
        "therapeutic",
        "based",
        "ionis",
        "proprietary",
        "antisense",
        "technology",
        "inotersen",
        "regulatory",
        "review",
        "eu",
        "treatment",
        "hereditary",
        "amyloid",
        "transthyretin",
        "amyloidosis",
        "hattr",
        "amyloidosis",
        "volanesorsen",
        "regulatory",
        "review",
        "eu",
        "canada",
        "treatment",
        "familial",
        "chylomicronemia",
        "syndrome",
        "fcs",
        "currently",
        "phase",
        "clinical",
        "development",
        "treatment",
        "familial",
        "partial",
        "lipodystrophy",
        "fpl",
        "akcea",
        "building",
        "infrastructure",
        "commercialize",
        "drug",
        "globally",
        "akcea",
        "global",
        "company",
        "headquartered",
        "cambridge",
        "massachusetts",
        "additional",
        "information",
        "akcea",
        "available",
        "statement",
        "press",
        "release",
        "includes",
        "statement",
        "regarding",
        "business",
        "akcea",
        "therapeutic",
        "therapeutic",
        "commercial",
        "potential",
        "inotersen",
        "volanesorsen",
        "product",
        "development",
        "statement",
        "describing",
        "akcea",
        "goal",
        "expectation",
        "financial",
        "projection",
        "intention",
        "belief",
        "statement",
        "considered",
        "statement",
        "statement",
        "subject",
        "certain",
        "risk",
        "uncertainty",
        "particularly",
        "inherent",
        "process",
        "discovering",
        "developing",
        "commercializing",
        "drug",
        "safe",
        "effective",
        "use",
        "human",
        "therapeutic",
        "endeavor",
        "building",
        "business",
        "around",
        "drug",
        "akcea",
        "statement",
        "also",
        "involve",
        "assumption",
        "never",
        "materialize",
        "prove",
        "correct",
        "could",
        "cause",
        "result",
        "differ",
        "materially",
        "expressed",
        "implied",
        "statement",
        "although",
        "akcea",
        "statement",
        "reflect",
        "good",
        "faith",
        "judgment",
        "management",
        "statement",
        "based",
        "fact",
        "factor",
        "currently",
        "known",
        "akcea",
        "result",
        "cautioned",
        "rely",
        "statement",
        "risk",
        "concerning",
        "akcea",
        "program",
        "described",
        "additional",
        "detail",
        "annual",
        "report",
        "form",
        "year",
        "ended",
        "december",
        "file",
        "sec",
        "press",
        "release",
        "unless",
        "context",
        "requires",
        "otherwise",
        "ionis",
        "akcea",
        "company",
        "company",
        "u",
        "refers",
        "ionis",
        "pharmaceutical",
        "akcea",
        "therapeutic",
        "ionis",
        "trademark",
        "ionis",
        "pharmaceutical",
        "akcea",
        "trademark",
        "akcea",
        "therapeutic",
        "medium",
        "investor",
        "contact",
        "kathleen",
        "gallagher",
        "head",
        "communication",
        "investor",
        "relation",
        "kgallagher",
        "source",
        "akcea",
        "therapeutic",
        "inc"
    ]
}